Adalimumab for Psoriasis: Efficacy, Dosage, and Treatment Guide
Understanding adalimumab: A TNF inhibitor biologic for moderate to severe psoriasis treatment.
Adalimumab for Psoriasis: A Comprehensive Treatment Overview
Adalimumab is a recombinant human monoclonal antibody that belongs to the class of biologic medicines known as tumour necrosis factor (TNF) inhibitors. It has become an important therapeutic option for patients with moderate to severe psoriasis who have not responded adequately to conventional treatments. This medication represents a significant advancement in dermatological care, offering sustained relief and improved quality of life for many patients struggling with this chronic inflammatory skin condition.
Drug Classification and Approval Status
Adalimumab is approved for use in adults and children over 4 years of age across multiple inflammatory conditions. Beyond psoriasis, regulatory authorities have authorized its use for treating psoriatic arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, rheumatoid arthritis, ulcerative colitis, Crohn disease, and uveitis. In September 2015, the FDA expanded approval to include hidradenitis suppurativa, another chronic inflammatory skin disorder.
The original brand name for adalimumab is Humira®, though generic biosimilar versions have become available in several countries, improving accessibility for patients worldwide. In New Zealand, PHARMAC (the Pharmaceutical Management Agency) approved funding in October 2019 through Special Authority application for specific circumstances, including severe treatment-resistant psoriasis, moderate to severe hidradenitis suppurativa, Behçet syndrome, and pyoderma gangrenosum.
Mechanism of Action
Adalimumab works through a precise biological mechanism that distinguishes it from conventional systemic treatments. As a recombinant monoclonal antibody containing only human peptides, adalimumab directly binds to TNF (tumor necrosis factor) molecules in the blood and diseased tissue. By capturing TNF molecules, the medication prevents them from triggering the inflammatory cascade that results in the formation of psoriasis plaques. This targeted approach allows for selective immunosuppression while theoretically preserving much of the body’s broader immune function.
TNF is a key inflammatory cytokine that drives the pathogenesis of psoriasis. By neutralizing TNF activity, adalimumab reduces the inflammatory signals that promote keratinocyte proliferation and immune cell infiltration into the skin. This mechanism has proven effective not only for psoriasis but also for other TNF-mediated inflammatory diseases, making adalimumab a versatile biologic agent in dermatological and rheumatological practice.
Dosage and Administration
The administration of adalimumab has been designed for patient convenience and compliance, utilizing subcutaneous injections rather than intravenous infusions. The recommended dosing schedule for psoriasis treatment follows this protocol:
- Initial loading dose: 80 mg administered as the first injection
- Second dose: 40 mg given one week after the initial dose
- Maintenance therapy: 40 mg administered every two weeks (fortnightly) as a single dose
Patients receive adalimumab through pre-prepared syringes or injection pens, which simplifies the administration process. After receiving appropriate counseling and training from healthcare professionals, most patients can self-administer injections into the thigh or abdomen. To minimize injection site discomfort and prevent tissue damage, patients should rotate injection sites with each administration, avoiding repeated injections at the same location.
Clinical Efficacy in Psoriasis
Extensive clinical trial data demonstrates the significant effectiveness of adalimumab in treating moderate to severe psoriasis. The efficacy has been consistently measured using the Psoriasis Area and Severity Index (PASI), a standardized assessment tool that evaluates both the extent and severity of psoriatic involvement.
Key efficacy findings from clinical studies include:
- More than 70% of patients achieved a 75% reduction in PASI score (PASI 75) at 16 weeks of treatment
- In 15–20% of patients, psoriasis cleared completely, achieving PASI 100 response
- Approximately 80% of patients receiving adalimumab demonstrated PASI 75 response compared to 36% with methotrexate and 19% with placebo in comparative trials
- The mean PASI improvement from baseline was maintained at approximately 90% through extended treatment periods
- Nearly 23% of patients achieved complete clearance of psoriasis through 24 weeks of therapy
Treatment of Psoriatic Arthritis
Beyond cutaneous psoriasis, adalimumab at a dose of 40 mg every two weeks has been studied in several hundred patients with psoriatic arthritis. The results indicate that most patients experience improvement in joint pain and swelling in at least some of their affected joints. Many patients report remarkable clinical benefit, with substantial reduction in arthralgia and improved functional capacity. This dual benefit—improvement in both skin and joint manifestations—makes adalimumab particularly valuable for patients presenting with both psoriasis and psoriatic arthritis.
Long-Term Treatment Considerations
It is important to understand that adalimumab is not a cure for psoriasis and requires long-term continuation to maintain therapeutic benefit. While the medication continues to be effective in the majority of patients throughout extended treatment periods, some patients may experience recurrence of psoriasis despite ongoing injections. This phenomenon is referred to as “secondary failure” and may necessitate adjustment of treatment strategies or consideration of alternative biologic agents.
Discontinuation of adalimumab therapy is typically associated with loss of the therapeutic response, with psoriasis symptoms gradually returning to pre-treatment levels. Therefore, patients and healthcare providers must maintain ongoing commitment to the treatment regimen to sustain the benefits achieved.
Combination Therapy
Adalimumab can be used effectively in combination with other systemic treatments. Other medications including methotrexate and acitretin can usually be continued during treatment with adalimumab without significant adverse interactions. This flexibility allows dermatologists to optimize treatment outcomes by combining agents with complementary mechanisms of action, potentially enhancing overall efficacy for particularly refractory cases.
Pre-Treatment Evaluation
Before initiating adalimumab therapy, dermatologists typically request several baseline investigations to ensure patient safety and establish a reference point for monitoring:
- Routine blood count (complete blood cell count)
- Liver function tests
- Renal function assessment
- Fasting lipid profile
- Antinuclear antibody (ANA) testing
- Pregnancy test in females of childbearing potential
These investigations help identify patients at higher risk for complications and provide baseline values for comparison during treatment monitoring.
Immunization Considerations
Immunization status should be reviewed prior to starting treatment with biological agents. If necessary, vaccines should be updated before initiating adalimumab therapy. Annual influenza vaccination is recommended for patients receiving TNF inhibitor therapy. Live vaccines should generally be avoided in patients receiving biologics, as these agents can impair the immune response to live viral vaccines.
Safety Profile and Side Effects
Adalimumab appears to be well tolerated in most patients. Mild to moderate injection site reactions represent the most common adverse effect, occurring in approximately 20% of patients. These reactions typically manifest as redness, swelling, itching, or pain at the injection site and are usually self-limited, resolving within hours to days.
Mild to serious infections represent the primary safety concern with adalimumab therapy and should be promptly identified and treated. Because adalimumab works by selectively targeting TNF, theoretically it should not substantially impair the remainder of the body’s immune system. However, caution must be exercised when considering its use in patients with a history of infections or those with active chronic or recurrent infections.
The risk of infection increases when adalimumab is used concurrently with corticosteroids, azathioprine, or ciclosporin. Infections associated with TNF inhibitor therapy can result from bacterial, mycobacterial, invasive fungal (including disseminated or extrapulmonary histoplasmosis, aspergillosis, and coccidioidomycosis), viral, parasitic, or other opportunistic infectious agents.
Perioperative Management
Patients who require major surgical procedures may be advised to discontinue adalimumab temporarily for 2–3 months prior to the planned operation. This allows the medication to clear from the system, potentially reducing infection risk during the perioperative period. Treatment can typically be resumed 2 weeks after surgery, provided that no infection has developed during the postoperative period.
Efficacy in Treatment-Resistant Cases
Adalimumab may prove effective even in patients who are refractory to other systemic agents. A clinical trial of 9 psoriatic patients who had failed previous anti-TNF therapies found that adalimumab was an effective treatment, with 62.5% reaching PASI 75 response at 20 weeks. This suggests that switching between different TNF inhibitors may be beneficial for some patients who develop resistance to one agent.
Pediatric Use
Adalimumab has demonstrated safety and efficacy in pediatric patients with severe psoriasis, along with other biologic agents such as etanercept and ustekinumab. The availability of effective biologic treatments for children represents an important advancement, as severe psoriasis in childhood can substantially impact growth, development, psychological well-being, and quality of life.
Quality of Life Improvements
Beyond objective clinical measures, research subjects receiving adalimumab report significant improvements in quality of life. Patients experience reduced symptoms, improved skin appearance, decreased joint pain and swelling, and enhanced psychosocial well-being. The impact extends to improved social functioning, reduced depression and anxiety related to visible skin disease, and greater confidence in personal and professional interactions.
Frequently Asked Questions
Q: How long does adalimumab take to work for psoriasis?
A: Clinical improvement typically becomes evident within the first few weeks of treatment, with significant responses occurring by 16 weeks. Maximum benefit is usually achieved after several months of consistent therapy.
Q: Can I stop adalimumab once my psoriasis clears?
A: Adalimumab requires long-term continuation to maintain therapeutic benefit. Discontinuing the medication typically results in recurrence of psoriasis symptoms, as the underlying disease remains present.
Q: What should I do if adalimumab stops working?
A: Secondary failure can occur in some patients. If this happens, your dermatologist may consider adjusting the dosing schedule, switching to an alternative TNF inhibitor, or exploring other biologic agents with different mechanisms of action.
Q: Are there restrictions on activities while using adalimumab?
A: Most patients can maintain normal activities. However, those with active infections or specific immunocompromised states should take precautions. Always inform healthcare providers about your adalimumab use before any surgery or medical procedures.
Q: How much does adalimumab cost and is it covered by insurance?
A: Adalimumab is expensive, which is why access is typically restricted to patients with moderate to severe psoriasis where conventional treatments are ineffective. Coverage varies by country and insurance provider. In New Zealand, PHARMAC provides funding through Special Authority application for eligible patients.
References
- Adalimumab for psoriasis — DermNet NZ. 2024. https://dermnetnz.org/topics/adalimumab-for-psoriasis
- Treating psoriasis with adalimumab — PubMed Central, National Institutes of Health. 2008. https://pmc.ncbi.nlm.nih.gov/articles/PMC2504074/
- The treatment of psoriasis in primary care — Best Practice Journal (BPJ), New Zealand. September 2009. https://bpac.org.nz/bpj/2009/september/psoriasis.aspx
- Biological agents for psoriasis — DermNet NZ. 2024. https://dermnetnz.org/topics/biological-agents-for-psoriasis
- Psoriasis: Symptoms, Treatment, Images and More — DermNet NZ. 2024. https://dermnetnz.org/topics/psoriasis
Similar Articles
Read full bio of Sneha Tete
